New Horizon Health Limited (HK:6606) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
New Horizon Health Limited, a biotech firm specializing in cancer screening products in China, continues business operations despite the ongoing suspension of trading of its shares. The company is addressing audit issues and is in the process of appointing a new auditor, which has led to delays in publishing their 2023 Annual Results and 2024 Interim Results. They are committed to keeping shareholders informed and taking measures to resume trading as soon as possible.
For further insights into HK:6606 stock, check out TipRanks’ Stock Analysis page.